FeesSafety
Pluang+

Cass Information Systems rated BUY on strong freight prices and 38% EPS growth forecast.

Company Fundamentals
23 Oct 2026
Seeking Alpha
View Source
Bullish
Cass Information Systems rated BUY on strong freight prices and 38% EPS growth forecast.

Cass Information Systems received a BUY rating due to strong freight prices and better earnings per share (EPS) growth compared to peers. The company exceeded expectations in Q3 2026, with transportation dollars processed up 14.5% year-over-year and average freight invoice rising 17.2%. Cass justifies its premium valuation with a 38% forward EPS growth, record dividends, and a 2.3% forward yield. The main risk is a potential decline in freight rates, which could significantly impact earnings and revenue.

Cass Information Systems' Q3 2026 earnings beat and dividend news provide context for readers. For those following Industrials, here is Pluang's market snapshot as of Oct 23, 2026 19:31 WIB: Among 135 Industrials stocks, 36 rose and 94 fell. TRMD (TORM plc) gained 1.58% to USD 39.14 with a 99% buy order activity and a typical hold time of 24 days, contrasting with CNH Industrial N.V. which dropped 1.51% to USD 11.40 and a shorter hold time of 5 days. FLR (Fluor Corporation) also rose 1.52% to USD 44.08 with a 14-day hold time.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
44 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App